The Venture Codex

Participated · Series D · Aug 2026

Hopscotch Primary Care operates a technology-enabled primary care model serving rural communities across the southeastern United States. Founded in 2021, the company serves more than 15,000 patients through 12 clinical locations, with its largest concentration in rural Western North Carolina. Its model emphasizes same-day visits, 24/7 access to care teams, and proactive outreach supported by administrative and clinical technology. Hopscotch reports strong patient-facing metrics—Net Promoter Score of 89 and patient retention above 90%—and says it has driven medical-loss-ratio improvement of over 25 percentage points for patients in their first two years. That operating performance is already translating to profitable operations in Western North Carolina. The company plans to use recent funding to expand into additional rural markets and continue scaling its technology-powered operations.

Participated · Series B · Sep 2025

Founded in 2022, Imagine Pediatrics operates one of the nation’s largest multidisciplinary pediatric practices focused on children with complex medical, behavioral, and social needs. Its proprietary technology platform connects families with round-the-clock virtual and in-home teams offering services ranging from pharmacy and nutrition to palliative care and social support. The company partners with health plans under value-based arrangements and has already completed nearly 300,000 patient encounters, caring for approximately 40,000 children nationwide. In 2024 alone, these programs cut emergency department visits and avoidable hospital admissions enough to save partners more than $65 million. Families endorse the service with a Net Promoter Score above 86, underscoring strong patient satisfaction. New capital will be used to accelerate national expansion, advance the technology platform, and drive further clinical innovation aimed at closing pediatric care gaps.

Participated · Equity · Apr 2023

Cortica delivers whole-child, value-based autism care through an integrated clinical model that spans medical treatment, neurodiversity-affirming behavioral therapy, developmental therapies (speech, occupational, physical, and music), and family support. The company addresses conditions that frequently co-occur with autism, including sleep disorders, seizures, psychiatric comorbidities, gastrointestinal, communication, behavioral, and sensorimotor issues. Cortica employs more than 1,800 experts across disciplines, including pediatric neurologists, developmental pediatricians, epileptologists, nurse practitioners, speech-language pathologists, occupational and physical therapists, music therapists, BCBA clinicians, and marriage and family therapists. Researchers and physicians in its Cortica innovation network conduct outcomes research, lead clinical trial recruitment, and have assembled a large longitudinal and cross-sectional dataset in autism and neurodevelopment. The company intends to use new funding to continue national scaling of whole-child autism value-based care and to invest in technology, data capture, clinical decision support, research, and optimization of the clinician and patient experience. Cortica is led by CEO and MD Neil Hattangadi and was founded to address the fragmented care journey families experience when seeking autism diagnoses and treatment. Cortica, founded in 2017 and based in San Diego, CA, is a physician-led autism services provider that blends pediatric neurology, developmental pediatrics, research-based therapies, and technology into integrated care programs. The company operates a network of clinicians including pediatric neurologists, developmental pediatricians, nurse practitioners, therapists, and behavior analysts. Cortica has built the Cortica Innovation Network to conduct outcomes research and support clinical trial recruitment. Through organic growth and acquisitions it now owns and operates 23 integrated autism centers and will serve more than 10,000 neurodivergent children and families this year. The organization employs more than 1,600 staff across clinical and support roles. Leadership is headed by CEO Neil Hattangadi. Cortica delivers a “whole-child” medical and behavioral care model for autism and other neurodiverse conditions, integrating medical advances with behavioral analysis, developmental therapies, and family support. Its care platform is enabled by Axon, a technology infrastructure for care coordination and data capture. The company operates centers across five states—California, Illinois, New Jersey, New York and Texas—each led by neurologists and other physicians. Cortica is running multiple clinical trials, including several funded by the National Institutes of Health, across neuroimaging, neuromodulation, molecular diagnostics, biotech therapeutics, and digital therapeutics. The company plans to use new investment to bring its care model to more families across the country. Leadership is headed by co-founder and CEO Neil Hattangadi, M.D. Cortica is a tech-enabled clinical services provider delivering coordinated care for autism and other neurodevelopmental conditions. Its treatment model assembles multidisciplinary teams to foster holistic child development and empower families. The model combines an “inside out” focus on medical diagnosis, nutrition, supplements, neurofeedback and other health interventions with an “outside-in” focus on environmental and learning optimizations such as speech and language therapy, neurological music therapy, occupational therapy, progressive ABA, and parent education. Cortica conducts sponsored and NIH-funded research and is considered a leader in autism outcomes research, having run multiple clinical studies demonstrating therapeutic benefits and cost-effectiveness of its platform. The company is accelerating growth by expanding centers across multiple states. Cortica is led by co-founders Neil Hattangadi, M.D. (CEO) and Suzanne Goh, M.D., BCBA (Chief Medical Officer), who met at Harvard Medical School.

Participated · Series A · Mar 2023

SpectrumAi builds software to modernize Applied Behavior Analysis (ABA) by capturing and measuring objective treatment and outcomes data. Its core products are Twyll, an ABA electronic health record, and Patterns, a network analytics platform designed to improve data capture and measurement. Both products were built from scratch and have been live in-market less than 18 months from the company’s launch. The company aims to increase supervisor efficiency and capacity and to enable providers to enter into value-based contracts with payors. SpectrumAi positions itself as the source of quality data capture and actionable insights to help payors, providers, patients and families receive better care. The recent financing is intended to accelerate adoption of its products and support a transition from fee-for-service to value-based contracting in ABA. SpectrumAi develops technology that captures objective quality and outcomes data for Applied Behavior Analysis (ABA) therapy to improve individual care and population-level insights. Its platform is designed to enable value-based contracting by producing standardized metrics that facilitate conversations among providers, payors, parents and the neurodiverse community. The data collection aims to surface care needs for underdiagnosed groups, including females and minorities with autism. The company positions its product as addressing variability in ABA quality and the current lack of objective data standards. SpectrumAi cites a national context of rising autism prevalence, widespread provider shortages (more than half of U.S. counties have zero supervisory BCBAs and 49 states miss per-capita benchmarks), and universal state mandates for ABA coverage that have driven demand. Leadership includes founder and CEO Ling Shao, co-founders Elizabeth Bigham and Chris Storer, and several healthcare executives and investor partners on the board.

Participated · Series A · Nov 2022

Floreo develops virtual-reality-based therapeutic experiences designed to help people with autism build social and communication skills within controlled immersive environments. The company is advancing its platform through an FDA review process and is using recent capital to continue product development while awaiting regulatory clearance. It received a $1 million investment from Cleveland Clinic Ventures, which the company says will support further technology development. Floreo plans to initiate a Series B financing round to secure additional funds for growth and expansion. The article does not report revenue, user counts, or other operating metrics. No founding year or location was provided in the article.